BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halon A, Donizy P, Biecek P, Rudno-Rudzinska J, Kielan W, Matkowski R. HER-2 expression in immunohistochemistry has no prognostic significance in gastric cancer patients. ScientificWorldJournal. 2012;2012:941259. [PMID: 22645475 DOI: 10.1100/2012/941259] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Irkkan C, Balci S, Güler Tezel G, Akinci B, Yalcin B, Güler G. Comparison of Clinicopathologic Parameters and Survivals Between Epstein-Barr Virus–positive and Her2-positive Gastric Cancers. Applied Immunohistochemistry & Molecular Morphology 2017;25:609-14. [DOI: 10.1097/pai.0000000000000353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
2 Satoh T, Xu R, Chung HC, Sun G, Doi T, Xu J, Tsuji A, Omuro Y, Li J, Wang J, Miwa H, Qin S, Chung I, Yeh K, Feng J, Mukaiyama A, Kobayashi M, Ohtsu A, Bang Y. Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment of HER2 -Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study. JCO 2014;32:2039-49. [DOI: 10.1200/jco.2013.53.6136] [Cited by in Crossref: 339] [Cited by in F6Publishing: 189] [Article Influence: 48.4] [Reference Citation Analysis]
3 Li X, Qi W, Yao R, Tang D, Liang J. Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin Transl Oncol 2014;16:307-14. [PMID: 23873251 DOI: 10.1007/s12094-013-1076-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
4 Pyo JS, Kang G, Park K. Clinicopathological significance and diagnostic accuracy of HER2 immunohistochemistry in colorectal cancer: a meta-analysis. Int J Biol Markers 2016;31:e389-94. [PMID: 27102863 DOI: 10.5301/jbm.5000208] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Chen L, Shi Y, Yuan J, Han Y, Qin R, Wu Q, Jia B, Wei B, Wei L, Dai G. HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PLoS One. 2014;9:e90678. [PMID: 24614305 DOI: 10.1371/journal.pone.0090678] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
6 Zhang X, Cui L, Ye G, Zheng T, Song H, Xia T, Yu X, Xiao B, Le Y, Guo J. Gastric juice microRNA-421 is a new biomarker for screening gastric cancer. Tumour Biol. 2012;33:2349-2355. [PMID: 22926798 DOI: 10.1007/s13277-012-0497-x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
7 Yoshida H, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Arch. 2014;465:145-154. [PMID: 24889042 DOI: 10.1007/s00428-014-1597-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 4.4] [Reference Citation Analysis]
8 Wang HB, Liao XF, Zhang J. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis. Medicine (Baltimore). 2017;96:e8437. [PMID: 29095284 DOI: 10.1097/md.0000000000008437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
9 Zhu B, Wu JR, Zhou XP. A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients. Medicine (Baltimore). 2015;94:e1428. [PMID: 26313797 DOI: 10.1097/md.0000000000001428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kotani D, Shitara K. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol 2021;13:1758835920986518. [PMID: 33473250 DOI: 10.1177/1758835920986518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Riquelme I, Saavedra K, Espinoza JA, Weber H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC, Bizama C. Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget 2015;6:24750-79. [PMID: 26267324 DOI: 10.18632/oncotarget.4990] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 15.6] [Reference Citation Analysis]
12 Wu H, Cai Z, Lu G, Cao S, Huang H, Jiang Y, Sun W. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis. Tumori 2017;103:249-54. [PMID: 26549693 DOI: 10.5301/tj.5000444] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
13 Bissinger O, Kolk A, Drecoll E, Straub M, Lutz C, Wolff KD, Götz C. EGFR and Cortactin: Markers for potential double target therapy in oral squamous cell carcinoma. Exp Ther Med 2017;14:4620-6. [PMID: 29201160 DOI: 10.3892/etm.2017.5120] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Li X, Qiu W, Liu B, Yao R, Liu S, Yao Y, Liang J. Forkhead box transcription factor 1 expression in gastric cancer: FOXM1 is a poor prognostic factor and mediates resistance to docetaxel. J Transl Med 2013;11:204. [PMID: 24004449 DOI: 10.1186/1479-5876-11-204] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 5.4] [Reference Citation Analysis]
15 Oh HS, Eom DW, Kang GH, Ahn YC, Lee SJ, Kim JH, Jang HJ, Kim EJ, Oh KH, Ahn HJ. Prognostic implications of EGFR and HER-2 alteration assessed by immunohistochemistry and silver in situ hybridization in gastric cancer patients following curative resection. Gastric Cancer. 2014;17:402-411. [PMID: 23955257 DOI: 10.1007/s10120-013-0288-0] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
16 Chrzanowska NM, Kowalewski J, Lewandowska MA. Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors. Molecules 2020;25:E1864. [PMID: 32316657 DOI: 10.3390/molecules25081864] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
17 Zhou F, Qiu W, Sun L, Xiang J, Sun X, Sui A, Ding A, Yue L. Clinical significance of nucleophosmin/B23 and human epidermal growth factor receptor 2/neu expressions in gastric cancers. APMIS. 2013;121:582-591. [PMID: 23489260 DOI: 10.1111/apm.12043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
18 Baiocchi GL, Molfino S, Baronchelli C, Giacopuzzi S, Marrelli D, Morgagni P, Bencivenga M, Saragoni L, Vindigni C, Portolani N, Botticini M, De Manzoni G. Recurrence in node-negative advanced gastric cancer: Novel findings from an in-depth pathological analysis of prognostic factors from a multicentric series. World J Gastroenterol 2017;23:8000-7. [PMID: 29259375 DOI: 10.3748/wjg.v23.i45.8000] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
19 Smolińska M, Grzanka D, Antosik P, Kasperska A, Neska-Długosz I, Jóźwicki J, Klimaszewska-Wiśniewska A. HER2, NF-κB, and SATB1 Expression Patterns in Gastric Cancer and Their Correlation with Clinical and Pathological Parameters. Dis Markers 2019;2019:6315936. [PMID: 31737131 DOI: 10.1155/2019/6315936] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Koganemaru S, Shitara K. Antibody-drug conjugates to treat gastric cancer. Expert Opin Biol Ther 2021;21:923-30. [PMID: 32713216 DOI: 10.1080/14712598.2020.1802423] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li Q, Jiang H, Li H, Xu R, Shen L, Yu Y, Wang Y, Cui Y, Li W, Yu S, Liu T. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget 2016;7:50656-65. [PMID: 27409420 DOI: 10.18632/oncotarget.10456] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
22 Xu C, Yue L, Wei H, Zhao W, Sui A, Wang X, Qiu W. Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. Pathology - Research and Practice 2013;209:479-85. [DOI: 10.1016/j.prp.2013.04.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
23 Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget. 2017;8:57654-57669. [PMID: 28915702 DOI: 10.18632/oncotarget.14825] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
24 Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17:1-12. [PMID: 23563986 DOI: 10.1007/s10120-013-0252-z] [Cited by in Crossref: 158] [Cited by in F6Publishing: 130] [Article Influence: 19.8] [Reference Citation Analysis]
25 Li Q, Lv M, Jiang H, Wang Y, Yu S, Li W, Yu Y, Liu T. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol 2020;146:287-95. [DOI: 10.1007/s00432-019-03060-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]